ZimVie Inc
ZimVie Inc., together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to support dental tooth replacement and restoration procedures worldwide. The company offers dental implant systems and biomaterials; digital dentistry solutions; restorative and abutment products, surgical instrumentation, and kits; and patient-specific restorative solu… Read more
ZimVie Inc (ZIMV) - Net Assets
Latest net assets as of June 2025: $412.80 Million USD
Based on the latest financial reports, ZimVie Inc (ZIMV) has net assets worth $412.80 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($758.22 Million) and total liabilities ($345.42 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $412.80 Million |
| % of Total Assets | 54.44% |
| Annual Growth Rate | -25.53% |
| 5-Year Change | -74.39% |
| 10-Year Change | N/A |
| Growth Volatility | 19.86 |
ZimVie Inc - Net Assets Trend (2019–2024)
This chart illustrates how ZimVie Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ZimVie Inc (2019–2024)
The table below shows the annual net assets of ZimVie Inc from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $381.71 Million | -6.79% |
| 2023-12-31 | $409.49 Million | -46.02% |
| 2022-12-31 | $758.60 Million | -47.73% |
| 2021-12-31 | $1.45 Billion | -2.62% |
| 2020-12-31 | $1.49 Billion | -10.65% |
| 2019-12-31 | $1.67 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to ZimVie Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 46663900000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $277.00K | 0.07% |
| Other Comprehensive Income | $-90.56 Million | -23.73% |
| Other Components | $938.63 Million | 245.90% |
| Total Equity | $381.71 Million | 100.00% |
ZimVie Inc Competitors by Market Cap
The table below lists competitors of ZimVie Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Harbin Xinguang Optic Electronics
SHG:688011
|
$411.35 Million |
|
Metro Healthcare Indonesia
JK:CARE
|
$411.41 Million |
|
Shenzhen hongfuhan Technology Co. Ltd.
SHE:301086
|
$411.57 Million |
|
Mesabi Trust
NYSE:MSB
|
$411.57 Million |
|
IRPC Public Company Limited
BK:IRPC
|
$411.27 Million |
|
QuantumScape Corporation
SA:Q2SC34
|
$411.16 Million |
|
Sparebanken Møre
OL:MORG
|
$411.12 Million |
|
Shenzhen Prolto Supply Chain Management Co Ltd
SHE:002769
|
$411.09 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ZimVie Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 409,493,000 to 381,707,000, a change of -27,786,000 (-6.8%).
- Net loss of 25,825,000 reduced equity.
- Other comprehensive income decreased equity by 17,601,000.
- Other factors increased equity by 15,640,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-25.82 Million | -6.77% |
| Other Comprehensive Income | $-17.60 Million | -4.61% |
| Other Changes | $15.64 Million | +4.1% |
| Total Change | $- | -6.79% |
Book Value vs Market Value Analysis
This analysis compares ZimVie Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.36x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.30x to 1.36x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | $63.88 | $18.99 | x |
| 2020-12-31 | $57.11 | $18.99 | x |
| 2021-12-31 | $55.61 | $18.99 | x |
| 2022-12-31 | $29.08 | $18.99 | x |
| 2023-12-31 | $15.48 | $18.99 | x |
| 2024-12-31 | $13.93 | $18.99 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ZimVie Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -6.77%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -5.74%
- • Asset Turnover: 0.60x
- • Equity Multiplier: 1.97x
- Recent ROE (-6.77%) is above the historical average (-21.91%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -1.67% | -2.64% | 0.50x | 1.27x | $-194.62 Million |
| 2020 | -12.01% | -19.62% | 0.47x | 1.31x | $-328.05 Million |
| 2021 | -6.57% | -9.39% | 0.56x | 1.26x | $-240.44 Million |
| 2022 | -8.42% | -6.99% | 0.56x | 2.16x | $-139.74 Million |
| 2023 | -96.04% | -85.98% | 0.38x | 2.94x | $-434.23 Million |
| 2024 | -6.77% | -5.74% | 0.60x | 1.97x | $-64.00 Million |
Industry Comparison
This section compares ZimVie Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ZimVie Inc (ZIMV) | $412.80 Million | -1.67% | 0.84x | $411.28 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |